消化器疾患治療薬の世界市場2016-2020

◆英語タイトル:Global Gastrointestinal Therapeutics Market 2016-2020
◆商品コード:IRTNTR10476
◆発行会社(調査会社):Technavio
◆発行日:2016年9月30日
◆ページ数:102
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、消化器疾患治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、消化器疾患治療薬の世界市場規模及び予測、疾患種類別分析、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Gastrointestinal Disorders
Gastrointestinal disorders include both functional and motility disorders affecting the gastrointestinal tract. Functional disorders involve an abnormality in the working of the gastrointestinal tract. They are the most common type of disorders and present with disturbances in motility, visceral hypersensitivity, changes in the mucosal and immune function, variations in central nervous system processing, and altered gut microbiota. Motility disorders are characterized by changes in the movement of the gastrointestinal tract and the transfer of its contents. Some of the most common gastrointestinal functional and motility disorders include IBS, GERD, Crohn’s disease, ulcerative colitis, and peptic ulcers.

Technavio’s analysts forecast the global gastrointestinal therapeutics market to grow at a CAGR of 6.5% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global gastrointestinal therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of various gastrointestinal disorders including IBD, and irritable bowel syndrome (IBS).

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Gastrointestinal Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AbbVie
• Johnson & Johnson
• Takeda
• Allergan
• UCB

[Other prominent vendors]
• 4SC
• Ajinomoto Pharmaceuticals
• Alfa Wassermann
• Alizyme
• Amgen
• Anterogen
• Ardelyx
• Arena Pharmaceuticals
• Astellas
• AstraZeneca
• Astellas Pharma
• Avaxia Biologics
• Biogen Idec
• BioLineRx
• Celgene
• ChemoCentryx
• Cosmo Pharmaceuticals
• Drais Pharmaceuticals
• Eisai
• Eli Lilly
• Enlivex Therapeutics
• F. Hoffmann-La Roche
• Ferring Pharmaceuticals
• FF Pharma
• Galapagos
• Gilead Sciences
• GlaxoSmithKline
• Hutchison Medi Pharma
• Immune Pharmaceuticals
• InDex Pharmaceuticals
• Ironwood Pharmaceuticals
• Kaken Pharmaceutical
• Kang Stem Biotech
• Kissei Pharmaceutical
• Kyowa Hakko Kirin
• Lexicon Pharmaceuticals
• Lipid Therapeutics
• Meda
• Merck
• Mesoblast
• Mitsubishi Tanabe
• Mochida Pharmaceutical
• Morphotek
• Neovacs
• Nestle
• Norgine
• Novartis
• Ono Pharmaceutical
• Pfizer
• Procter & Gamble
• Qu Biologics
• Receptos
• RedHill Biopharma
• Salix Pharmaceuticals
• Shield Therapeutics
• Sterna Biologicals
• Synergy Pharmaceuticals
• Synthetic Biologics
• TiGenix
• Tillotts Pharma
• TopiVert
• TSD Japan
• Zeria Pharmaceutical

[Market driver]
• Tentative approval of late stage molecules
• For a full, detailed list, view our report

[Market challenge]
• Discontinuation of drugs under development and from the market
• For a full, detailed list, view our report

[Market trend]
• Emergence of biosimilars
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01:Executive summary
• Highlights

PART 02:Scope of the report
• Market overview
• Top-vendor offerings

PART 03:Market research methodology
• Research methodology
• Economic indicators

PART 04:Introduction
• Key market highlights

PART 05:Pipeline portfolio
• Ulcerative colitis
• Crohn’s disease
• IBS

PART 06:Market landscape
• Global gastrointestinal therapeutics market

PART 07:Market segmentation by disease type
• Overview

PART 08:Global IBD therapeutics market
• Global ulcerative colitis drugs market
• Global Crohn’s disease drugs market
• Market segmentation by molecule type

PART 09:Global IBS therapeutics market

PART 10:Global gastrointestinal OTC drugs market

PART 11:Geographical segmentation
• Global gastrointestinal therapeutics market by geography 2015-2020
• Gastrointestinal therapeutics market in Americas
• Gastrointestinal therapeutics market in EMEA
• Gastrointestinal therapeutics market in APAC

PART 12:Market drivers
• Increasing consumption of biologics
• Tentative approval of late stage molecules
• Development of novel therapies using innovative technologies
• Improved diagnostic tools increasing the treatment-seeking population

PART 13:Impact of drivers

PART 14:Market challenges
• Increased consumption of OTC medications
• Unknown etiology of IBD and IBS
• Discontinuation of drugs under development and from the market

PART 15:Impact of drivers and challenges

PART 16:Market trends
• Patient assistance programs
• Emergence of biosimilars
• Rise in self-medication
• Focus on regenerative medicines
• Strategic alliances and M&A

PART 17:Vendor landscape
• Competitive scenario
• Other prominent vendors

PART 18:Key vendor analysis
• AbbVie
• Johnson & Johnson
• Takeda
• Allergan
• UCB

PART 19:Appendix
• List of abbreviations

PART 20:Explore Technavio

[List of Exhibits]

Exhibit 01:Product offerings
Exhibit 02:Global gastrointestinal therapeutics market: Key buying criteria 2015
Exhibit 03:Global gastrointestinal therapeutics market: Key customer segments
Exhibit 04:Global ulcerative colitis therapeutics market: Pipeline portfolio
Exhibit 05:Global Crohn’s disease therapeutics market: Pipeline portfolio
Exhibit 06:Global IBS therapeutics market: Pipeline portfolio
Exhibit 07:Global gastrointestinal therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 08:Global gastrointestinal therapeutics market: Factors affecting growth 2015 and 2020
Exhibit 09:Approval and patent expiries of top selling biologics
Exhibit 10:Global gastrointestinal therapeutics market 2016-2020 ($ billions)
Exhibit 11:Global gastrointestinal disorder therapeutics market segmentation: Growth cycle analysis
Exhibit 12:Five forces analysis
Exhibit 13:Global gastrointestinal therapeutics market by disease type: Revenue share 2015
Exhibit 14:Global gastrointestinal therapeutics market by disease type: Growth lifecycle analysis
Exhibit 15:Global gastrointestinal therapeutics market by disease type 2015-2020
Exhibit 16:Global IBD therapeutics market by type: Revenue share 2015
Exhibit 17:Global IBD therapeutics market by type 2015-2020
Exhibit 18:Global IBD therapeutics market segmentation: Growth lifecycle analysis
Exhibit 19:Global ulcerative colitis drugs market 2015-2020 ($ billions)
Exhibit 20:Global Crohn’s disease drugs market 2015-2020 ($ billions)
Exhibit 21:Global IBD therapeutics market by molecule type 2015
Exhibit 22:Biologics in global IBD therapeutics market 2015-2020 ($ billions)
Exhibit 23:Small molecules in global IBD therapeutics market 2015-2020 ($ billions)
Exhibit 24:Global IBS therapeutics market 2015-2020 ($ billions)
Exhibit 25:Drugs that underwent Rx-to-OTC switch in the US
Exhibit 26:Global gastrointestinal OTC drugs market 2015-2020 ($ billions)
Exhibit 27:Global gastrointestinal therapeutics market by geography 2015-2020
Exhibit 28:Global gastrointestinal therapeutics market by geography 2015 and 2020
Exhibit 29:Global gastrointestinal therapeutics market by geography 2015-2020 ($ billions)
Exhibit 30:Global gastrointestinal therapeutics market by geography: Market share 2015
Exhibit 31:Global gastrointestinal therapeutics market by geography: Disease type 2015
Exhibit 32:Global gastrointestinal therapeutics market by geography: Market growth lifecycle analysis 2015
Exhibit 33:Global gastrointestinal therapeutics market by country: Revenue and growth rate analysis
Exhibit 34:Opportunity analysis of gastrointestinal therapeutics market in Americas
Exhibit 35:Gastrointestinal therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 36:Opportunity analysis of gastrointestinal therapeutics market in EMEA
Exhibit 37:Gastrointestinal therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 38:Opportunity analysis of gastrointestinal therapeutics market in APAC
Exhibit 39:Gastrointestinal therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 40:Impact of drivers and challenges on global gastrointestinal therapeutics market
Exhibit 41:Biologics for IBD: market share 2012-2022
Exhibit 42:Few biologics under development for gastrointestinal disorders
Exhibit 43:Impact of drivers
Exhibit 44:Rx-to-OTC switch: Promoters and inhibitors
Exhibit 45:Gastrointestinal therapeutics discontinued from development or market
Exhibit 46:Impact of drivers and challenges
Exhibit 47:Global gastrointestinal therapeutics market: Impact assessment of key trends
Exhibit 48:Gastrointestinal therapeutics with patient assistance programs in US
Exhibit 49:Biosimilars under development for gastrointestinal disorders
Exhibit 50:Regenerative medicines for IBD under development
Exhibit 51:Key vendors ranking 2015
Exhibit 52:Key vendors: Geographical presence
Exhibit 53:Market vendors: Competitive scenario 2015-2020
Exhibit 54:AbbVie: Profile
Exhibit 55:AbbVie: Strength analysis
Exhibit 56:AbbVie: Growth strategy matrix
Exhibit 57:AbbVie: Opportunity assessment
Exhibit 58:AbbVie: YoY growth and revenue of HUMIRA 2012-2014 ($ billions)
Exhibit 59:Johnson & Johnson: Profile
Exhibit 60:Johnson & Johnson: Strength analysis
Exhibit 61:Johnson & Johnson: Growth strategy matrix
Exhibit 62:Johnson & Johnson: Opportunity assessment
Exhibit 63:Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
Exhibit 64:Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 65:Takeda: Profile
Exhibit 66:Takeda: Strength analysis
Exhibit 67:Takeda: Growth strategy matrix
Exhibit 68:Takeda: Opportunity assessment
Exhibit 69:Allergan: Profile
Exhibit 70:Allergan: Strength analysis
Exhibit 71:Allergan: Growth strategy matrix
Exhibit 72:Allergan: Opportunity assessment
Exhibit 73:Allergan: Revenue of gastrointestinal therapeutics 2015 ($ millions)
Exhibit 74:UCB: Profile
Exhibit 75:UCB: Strength analysis
Exhibit 76:UCB: Growth strategy matrix
Exhibit 77:UCB: Opportunity assessment



【掲載企業】

AbbVie, Johnson & Johnson, Takeda, Allergan, UCB, 4SC, Ajinomoto Pharmaceuticals, Alfa Wassermann, Alizyme, Amgen, Anterogen, Ardelyx, Arena Pharmaceuticals, Astellas, AstraZeneca, Astellas Pharma, Avaxia Biologics, Biogen Idec, BioLineRx, Celgene, ChemoCentryx, Cosmo Pharmaceuticals, Drais Pharmaceuticals, Eisai, Eli Lilly, Enlivex Therapeutics, F. Hoffmann-La Roche, Ferring Pharmaceuticals, FF Pharma, Galapagos, Gilead Sciences, GlaxoSmithKline, Hutchison Medi Pharma, Immune Pharmaceuticals, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Kaken Pharmaceutical, Kang Stem Biotech, Kissei Pharmaceutical, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, Lipid Therapeutics, Meda, Merck, Mesoblast, Mitsubishi Tanabe, Mochida Pharmaceutical, Morphotek, Neovacs, Nestle, Norgine, Novartis, Ono Pharmaceutical, Pfizer, Procter & Gamble, Qu Biologics, Receptos, RedHill Biopharma, Salix Pharmaceuticals, Shield Therapeutics, Sterna Biologicals, Synergy Pharmaceuticals, Synthetic Biologics, TiGenix, Tillotts Pharma, TopiVert, TSD Japan, Zeria Pharmaceutical.

【レポートのキーワード】

消化器疾患、胃腸障害、消化器疾患治療薬、IBD、IBS、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[消化器疾患治療薬の世界市場2016-2020]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月11日現在 219,328 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆